Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
15.22
-0.79 (-4.93%)
Dec 20, 2024, 4:00 PM EST - Market closed
Prothena Corporation Revenue
Prothena Corporation had revenue of $970.00K in the quarter ending September 30, 2024, a decrease of -98.86%. This brings the company's revenue in the last twelve months to $133.35M, down -5.41% year-over-year. In the year 2023, Prothena Corporation had annual revenue of $91.37M with 69.50% growth.
Revenue (ttm)
$133.35M
Revenue Growth
-5.41%
P/S Ratio
6.13
Revenue / Employee
$770,809
Employees
173
Market Cap
818.97M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
Dec 31, 2020 | 853.00K | 39.00K | 4.79% |
Dec 31, 2019 | 814.00K | -141.00K | -14.76% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 5.59B |
Healthcare Services Group | 1.70B |
Paragon 28 | 245.00M |
Cytek Biosciences | 201.21M |
Avid Bioservices | 150.45M |
Immatics | 128.82M |
AbCellera Biologics | 32.96M |
uniQure | 28.59M |
PRTA News
- 3 days ago - Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease - Business Wire
- 5 weeks ago - Prothena Reports Third Quarter 2024 Financial Results and Business Highlights - Business Wire
- 6 weeks ago - Prothena to Report Third Quarter 2024 Financial Results on November 12 - Business Wire
- 3 months ago - Prothena Announces Leadership Team Updates - Business Wire
- 4 months ago - Prothena to Participate in Upcoming Healthcare Conferences - Business Wire
- 4 months ago - Prothena Reports Second Quarter 2024 Financial Results and Business Highlights - Business Wire
- 5 months ago - Prothena to Report Second Quarter 2024 Financial Results on August 8 - Business Wire
- 7 months ago - Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration - Business Wire